Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDA

Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDA

In an extraordinary step forward for the psychedelic drug research community, the US Food and Drug Administration (FDA) has just given psilocybin therapy for treatment-resistant depression a Breakthrough Therapy designation. This classification suggests the treatment has demonstrated significant potential in early clinical evidence, allowing the FDA to assist and expedite subsequent development and review processes.

Comments

Post a Comment

Popular posts from this blog

U.S. secretly tested carcinogen in Western Canada during the Cold War, researcher finds | National Post

U.S. secretly tested carcinogen in Western Canada during the Cold War, researcher finds | National Post Between July 9, 1953 and Aug 1, 1953, six kilograms of carcinogenic zinc cadmium sulfide was sprayed onto unsuspecting citizens of Winnipeg from U.S. Army planes. The US Army returned 11 years later and repeated the experiments in Suffield, Alberta and Medicine Hat, Alberta. Local governments had no knowledge of these experiments. Canadians were unwillingly used as lab rats by the people who are supposedly our closest ally.
Read more